Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
GenSight Biologics
company
About
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
- 11 - 50
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- €35M
- Industries
- Biotechnology,Genetics,Health Care,Medical
- Founded date
- Jan 1, 2012
- Number Of Employee
- 11 - 50
- Operating Status
- Active
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
€82M $36M
GenSight Biologics has raised a total of
€82M $36M
in funding over 2 rounds. Their latest funding was raised on
Nov 7, 2022 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 7, 2022 | Post-IPO Debt | €35M | 1 |
European Investment Bank
|
— | Detail |
| Dec 20, 2019 | Post-IPO Debt | €15M | 2 |
Kreos Capital
|
— | Detail |
| Jul 23, 2015 | Series B | $36M | 1 | — | — | Detail |
| Apr 8, 2013 | Series A | €32M | 1 |
Versant Ventures
|
— | Detail |
Investments
Number of Investments
Number of Lead Investments
1
0
GenSight Biologics has made 1 investments. Their most recent investment was on
Jan 18, 2019, when Hone raised $3.60M.
Investors
Number of Lead Investors
Number of Investors
3
4
GenSight Biologics is funded by 4 investors.
European Investment Bank
and Kreos Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
European Investment Bank
|
Yes | Post-IPO Debt |
|
Kreos Capital
|
Yes | Post-IPO Debt |
3sbio
|
— | Post-IPO Debt |
|
Versant Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
